RETATRUTIDE

Description

RETATRUTIDE is a  novel triple agonist (GLP-1, GIP, and glucagon receptors). Designed for obesity and type 2 diabetes treatment. Demonstrates significant weight loss and metabolic improvements in clinical trials.

Additional Information:
Dose: 5 & 10 mg per vial
Third- party tested
Made in Canada 

Endorsed or recommended by Dr Sanjeev Goel – Canada’s Longevity MD.  We believe in providing the highest quality peptides backed by science.